This webcast features: Scott Estes, Head of Cell Line Development, Asimov. Traditional cell line development to support bioprocessing has typically relied on a “one-size-fits-all” vector, which can streamline development, but in most cases can lead to suboptimal expression levels, particularly for complex multi-specific molecular architectures. The commercial consequences are increased cost of goods, reduced facility flexibility, and in the worst case the inability to support commercial demand. In this webinar, Asimov presents their CHO Edge platform, which builds on the…